Clinical trials: Borderline Personality Disorders
Borderline Personality Disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young…
- Trial name
- NCT01103180
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Borderline Personality Disorder
Brexpiprazole in Borderline Personality Disorder
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD).
- Trial name
- NCT03418675
- Testing
- Rexulti
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Borderline Personality Disorder
Mapping Aspects of Psychotherapy in Dialectical Behavior Therapy
Although dialectical behavior therapy (DBT) skills training is effective in the treatment of borderline personality disorder, it contains four skills modules and there is little research to guide their modular application.
- Trial name
- MAP-DBT (NCT04626310)
- Testing
- Dialectical behavior therapy - emotion regulation skills training, Dialectical behavior therapy - interpersonal effectiveness skills training, Interpersonal psychotherapy
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Massachusetts, Amherst